Abstract:Abstract Mutant BRAF, one of the most frequently mutated serine/threonine kinase, drives tumorigenesis via activating MAPK signaling across various tumor types. Expanded genomic and mechanistic studies over the past two decades have revealed the heterogeneity regarding BRAF mutation status and characterized a classification system for BRAF mutations based on their mode of action. Class I (V600 mutants) and class II (K601 mutants, G469A/V/R, etc) BRAF mutants function as RAS-independent active monomers or dimers to amplify MAPK signaling, whereas class III (G466 mutants, D594 mutants, G469E, etc) mutants, which are kinase impaired or dead, promote MAPK signaling via enhanced RAS binding and subsequent CRAF activation. To date, combination therapies of BRAF and MEK inhibitors have been approved for treatment of patients harboring class I BRAF mutations, while viable therapeutic options for those with class II and III BRAF mutations are still ambiguous. Therefore, developing new drugs and personalized therapeutic strategies directing different classes of BRAF mutations, especially class II and III subtypes, have become vital in the war against BRAF-mutant tumors. To enable BRAF-targeted drug discovery and precision medicine, we developed a tailored platform based on the classification of BRAF mutations, which integrates whole exome sequencing (WES) for identification of mutant BRAF subtypes with in vivo efficacy evaluation in patient-derived tumor xenograft (PDX) models. Our platform covers all three classes of BRAF mutants, such as V600E/G469A/D594N/G469E. Moreover, this platform faithfully recapitulate the responses of multiple targeted therapies, such as BRAF, MEK and EGFR inhibitors, reported for treating BRAF-mutant tumors in preclinical and clinical studies, highlighting the potential translation values. Taken together, the platform reported in this study empowers the discovery of novel BRAF inhibitors that can be translated into clinical trials and provides personalized therapeutic options for patients who have poorly responded to standard clinical therapies. Citation Format: Hui Qi, Fuyang Wang, Bingrui Han, Xiaomin Wang, Xiangnan Qiang, Zhixiang Zhang, Qingyang Gu. A tailored platform enables BRAF-targeted drug discovery and precision medicine. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 4988.

Targeted Disruption of V600E-Mutant BRAF Gene by CRISPR-Cpf1.

Targeting EGFR-L858R mutation by Cpf1 and Cas9 nuclease

Potential high-frequency off-target mutagenesis induced by CRISPR/Cas9 in <i>Arabidopsis</i> and its prevention

High-frequency off-target mutagenesis induced by CRISPR/Cas9 in Arabidopsis and its prevention by improving specificity of the tools

Potential high-frequency off-target mutagenesis induced by CRISPR/Cas9 in Arabidopsis and its prevention

Mutation-Specific CRISPR Targeting with SaCas9 and AsCas12a Restores Therapeutic Sensitivity in Treatment-Resistant Melanoma

Targeted Mutagenesis of Duplicated Genes in Caenorhabditis Elegans Using CRISPR-Cas9

Specific targeting of point mutations in EGFR L858R-positive lung cancer by CRISPR/Cas9

Selective Targeting of an Oncogenic KRAS Mutant Allele by CRISPR/Cas9 Induces Efficient Tumor Regression

Selective Targeting of the Oncogenic KRAS G12S Mutant Allele by CRISPR/Cas9 Induces Efficient Tumor Regression

Targeted Gene Disruption by CRISPR/xCas9 System in Drosophila Melanogaster.

Orthogonal Chemical Activation of Enzyme-Inducible CRISPR/Cas9 for Cell-Selective Genome Editing.

Targeting ABCB1-mediated Tumor Multidrug Resistance by CRISPR/Cas9-based Genome Editing.

Abstract 4988: A tailored platform enables BRAF-targeted drug discovery and precision medicine

Targeting Cancer with CRISPR/Cas9-Based Therapy

Precise and efficient silencing of mutant Kras<SUP>G12D</SUP> by CRISPR-CasRx controls pancreatic cancer progression

Abstract 6493: CRISPR-directed prime editing sensitizes EGFR inhibitor by correcting oncogenic KRAS mutants In NSCLC

The Targeted Degradation of BRAF V600E Reveals the Mechanisms of Resistance to BRAF-Targeted Treatments in Colorectal Cancer Cells

PAM-Flexible Genome Editing with an Engineered Chimeric Cas9.

Efficient Gene Editing at Major CFTR Mutation Loci